| Naptumomab estafenatox: a new immunoconjugate. | |
| | |
MedLine Citation:
|
PMID: 20053143 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
IMPORTANCE OF THE FIELD: New agents that specifically engage the immune system are being tested in a variety of malignancies. This review provides an overview of naptumomab, an immunotoxin, with encouraging clinical activity in Phase I trials. AREAS COVERED IN THIS REVIEW: This review examines the preclinical and the published clinical data with regards to naptumomab. WHAT THE READER WILL GAIN: This review provides the reader with an understanding of the mechanism of action, immunology, pharmacokinetics and clinical activity of this agent. TAKE HOME MESSAGE: Naptumomab has a unique mechanism of action and appears to be an active agent in the treatment of refractory solid tumors such as renal cell carcinoma. |
| | |
Authors:
|
Matthew K Robinson; R Katherine Alpaugh; Hossein Borghaei |
Related Documents
:
|
6864913 - Anatomy of the retroperitoneal connective tissue. 20931923 - Childhood bruxism: a clinical review and case report. 18204313 - Development of the dexaide right ventricular assist device inflow cannula. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on biological therapy Volume: 10 ISSN: 1744-7682 ISO Abbreviation: Expert Opin Biol Ther Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-01-21 Completed Date: 2010-04-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101125414 Medline TA: Expert Opin Biol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 273-9 Citation Subset: IM |
Affiliation:
|
Fox Chase Cancer Center, Department of Medical Oncology, 333 Cottman Ave, Philadelphia, PA 19111, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal / adverse effects, chemistry, pharmacokinetics, pharmacology, therapeutic use* Antineoplastic Agents / adverse effects, chemistry, pharmacokinetics, pharmacology, therapeutic use* Clinical Trials, Phase I as Topic Drug Design Enterotoxins / adverse effects, chemistry, pharmacokinetics, pharmacology, therapeutic use* Humans Immunoconjugates / adverse effects, chemistry, pharmacokinetics, pharmacology, therapeutic use* Neoplasms / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Enterotoxins; 0/Immunoconjugates; 676258-98-3/naptumomab estafenatox |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency viru...
Next Document: Combination therapy with angiotensin-converting enzyme inhibitors and indapamide impairs glucose tol...